Off the Shelf: Sapiens: A User's Manual for a Confused Species
Dr. Hari writes about a book that provides a compelling story of our species he believes every human could benefit from reading.
Can We Vaccinate Our Way Out of Multiple Myeloma Progression?
Drs. Tahri, Mouhieddine, and Ghobrial discuss studies that evaluate the efficacy of vaccination to prevent multiple myeloma progression.
Insightful critiques and informed commentary of important ongoing clinical trials
Drs. Luskin, DeAngelo, and Kim review a study that tests the clinical efficacy of combining an adolescent and young adult chemotherapy regimen with a novel antibody in the treatment of B-cell acute lymphoblastic leukemia.
Dr. DeBaun reviews a study that looks at outcomes for pregnant women with sickle cell disease who are randomly assigned to home-based oxygen therapy versus no home-based oxygen therapy.
Dr. Michaelis discusses a study that adds antibody therapy to a reduced-intensity conditioning regimen and protocol-specific allogeneic hematopoietic stem cell transplantation for patients with relapsed or refractory AML over the age of 55.
Drs. Sklavenitis Pistofidis and Ghobrial discuss a study that looks at a targeted approach to therapy for multiple myeloma patients carrying a t(1;14) translocation.
Dr. Moss discusses the CLARITY study, which looks at the combination of therapies venetoclax and ibrutinib to treat relapsed/refractory chronic lymphocytic leukemia.
Dr. Moll discusses a study that looks at the use of direct oral anticoagulants in patients with definite antiphospholipid syndrome.
Dr. Jacobson looks at a study that investigates the safety and efficacy of chimeric antigen receptor (CAR)- T cell therapy with KTE-C19 in combination with the anti-PD-L1 antibody atezolizumab in patients with refractory DLBCL.
Dr. Abdel-Wahab and Dr. Taylor look at a study that evaluates the safety of combining the anti-PD-L1 antibody atezolizumab with the novel hypomethylating agent guadecitabine in older adults with AML not eligible for standard induction therapy.
Dr. Keel breaks down a study that looks at the use and effects of two different doses of intravenous iron in patients with chronic kidney disease on hemodialysis.
Dr. Roberts looks at whether chemoimmunotherapy can be improved as a front-line therapy for chronic lymphocytic leukemia in fit patients.
September-October 2018Volume 15, Issue 5
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology